![Oren M. Becker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oren M. Becker
Direttore/Membro del Consiglio presso VIDAC PHARMA HOLDING PLC
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Max Herzberg | M | - |
Vidac Pharma Ltd.
![]() Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | 13 anni |
Yochai Richter | M | 81 |
Vidac Pharma Ltd.
![]() Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | - |
Joseph Tenne | M | 68 |
Vidac Pharma Ltd.
![]() Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | - |
Christian Policard | M | - |
Vidac Pharma Ltd.
![]() Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | - |
Sandra Gamzon | F | - |
Vidac Pharma Ltd.
![]() Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | 3 anni |
Morris Laster | M | 60 |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Batsheva Elran | F | 65 |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Amichai Steimberg | M | 62 | - | |
Yuval Sagiv | M | - | - | |
Ofer Shpilberg | M | - |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Gavin B Samuels | M | - |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Shuki Cohen | M | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Robert Spiegel | M | 73 |
Vidac Pharma Ltd.
![]() Vidac Pharma Ltd. Pharmaceuticals: MajorHealth Technology Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel. | - |
Efrat Shalom-Berensohn | F | - |
EPIX Pharmaceuticals, Inc.
![]() EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Israele | 10 | 71.43% |
Regno Unito | 8 | 57.14% |
Stati Uniti | 1 | 7.14% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Oren M. Becker
- Contatti personali